N Engl J Med 2005, 353: 2012–2024 CrossRefPubMed 16 Barber TD, V

N Engl J Med 2005, 353: 2012–2024.CrossRefPubMed 16. Barber TD, Vogelstein B, Kinzler KW: Somatic mutations of EGFR in

colorectal cancers and Glioblastomas. N Engl J Med 2004, 351: 2270–2883.CrossRef 17. Marie Y, Carpentier AF, Omuro AM: EGFR tyrosine kinase domain mutations in human gliomas. Neurology 2005, 64: 1444–1445.PubMed 18. Roberto B, Incheol S, Ritter ChristophA: Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003, 22: 2812–2822.CrossRef 19. Ingo K, Mellinghoff, Maria Y, Wang P: Molecular Determinants of the Response of Glioblastomas Volasertib solubility dmso to EGFR Kinase Inhibitors. N Engl J Med 2006, 354: 884–897. 20. Smith JustinS, Issei T, Sandra M: PTEN Mutation, EGFR Amplification, and Outcome in Patients With Anaplastic Astrocytoma and Glioblastoma Multiforme. J Natl Cancer Inst 2001, 93: 1246–1256.CrossRefPubMed 21. Harima Y, Sawada S, Nagata K: Mutation of the PTEN gene

in advanced cervical cancer correlated with tumor progression and poor outcome after radiotherapy. Int J Oncol 2001, 18: 493–497.PubMed 22. Endoh H, Yatabe Y, Kosaka T: PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment AP24534 supplier in EGFR-mutated lung cancer patients. J Thorac Oncol 2006, 1: 629–634.CrossRefPubMed 23. Baselga J, Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005, 23: 2445–2259.CrossRefPubMed Thymidine kinase 24. Russell Sambrook: olecular Cloning. Third edition. America: CSHL Press;

2000:1235–1262. 25. Fan Z, Masui H, Altas I: Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1993, 53: 4322–4328.PubMed 26. Fan Z, Lu Y, Wu X: Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 1994, 269: 27595–27602.PubMed 27. Prakash C, Shyhmin H, Geetha V: Mechanisms of Enhanced Radiation Response following EpidermalGrowth Factor Receptor Signaling Inhibition by Erlotinib (Tarceva). Cancer Res 2005, 65: 3328–3335. 28. Byeong HC, Chang GK, Yoongho L: Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt pathway. Cancer Letters 2008, 259: 111–118.CrossRef 29. Ivanco I, Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2: 489–501.CrossRef 30. Liu W, James CD, Frederick L: PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 1997, 57: 5254–5257.PubMed 31. Yakut T, Gutenberg A, Bekar A: Correlation of chromosomal imbalances by comparative genomic hybridization and expression of EGFR, PTEN, p53, and MIB-1 in diffuse gliomas. Oncol Rep 2007, 17: 1037–1043.PubMed 32.

Comments are closed.